The Australian Academy of Health and Medical Sciences elects the best and brightest minds in the field of medical and health sciences as Fellows.

Fellows are elected in recognition of their outstanding achievements and exceptional contributions to the sector. The Fellowship are acknowledged for their clinical, non-clinical, leadership, industry and research contributions.

About Fellowship with AAHMS

Find Fellows of the AAHMS

To find Fellows of our Academy either use the search form below or download the full list of current Fellows here.






Executive Director, Monash Partners Academic Health Sciences Centre, Director, Monash Centre For Health Research And Implementation
Monash University

Professor Teede is a clinician, academic, and leader committed to research and translation, delivering measurable changes in policy and practice. She is nationally and internationally recognised for excellence in health and medical research, exceptional leadership, and community engagement. Focusing on improving women’s reproductive health, she has spearheaded the development of the first evidence-based guidelines on PCOS in the world, pioneered interventions for preventing obesity in women, and established one of only four national Diabetes Centres of Excellence. Having raised a family and maintained an active academic and clinical career, she is a role model for women in her profession.



Director, Institute of Vector-Borne Disease / Director, Impact Assessment, World Mosquito Program
Monash University

Professor Cameron Simmons is an internationally recognised infectious disease scientist who has made an outstanding contribution to the understanding of dengue. He has been at the forefront of developing and testing novel approaches to improve individual patient outcomes through better diagnosis, prognosis and testing of new treatment options. As Director of Impact Assessment in the Eliminate Dengue Program, he is leading clinical and epidemiological research into Wolbachia for the biocontrol of dengue and Zika. His expertise in the field is recognised through appointments to technical committees at WHO, invitations to international meetings and advisory roles to academic and private sector entities.


Director, Department of Molecular Imaging and Therapy; Head, Tumour Targeting Laboratory
Austin Health, ONJCRI

Professor Andrew Scott has made significant contributions to science and medicine through the discovery of novel therapeutic antibodies that are impacting on cancer patient outcomes, and the development of evidence for positron emission tomography (PET) that has led to the approval of multiple Medicare clinical indications for accurately staging cancer patients. He has provided leadership of scientific and medical professional organisations and in public education. Professor Scott is recognised Internationally for his research and clinical expertise, and for advocacy of molecular imaging and therapy, reflected by his recent election as President of the World Federation of Nuclear Medicine and Biology.


Director, Southgate Institute of Health, Society & Equity
Flinders University

Baum is an international leader in public health social science. She has made major contributions to the understanding of the social determinants of health, health promotion and to the use of qualitative methods. She has published 179 refereed articles, 10 books, 40 book chapters, 68 reports for government or international agencies, and given 185 keynote or invited addresses. Her work is widely cited with 6056 citations (GS) and an H-index of 38 (GS). She is a Fellow of the Academy of Social Sciences in Australia and a Life Member of the Public Health Association.

College of Science
Australian National University

Professor Kiaran Kirk is Dean of the Australian National University’s College of Science. His primary research interest is in the biology of the malaria parasite with a particular focus on the mechanism of action of, and mechanisms of resistance to, antimalarial drugs. His work has had significant translational impact, with the biochemical assays that he and his colleagues have developed now being used to assess the mechanism of action of drugs entering the antimalarial drug-development pipeline, to ensure that that there is not overinvestment in compounds sharing the same molecular target


Professor of Hepatic Medicine
ANU Medical School at The Canberra Hospital

Geoff Farrell is an international authority on fatty liver associated with overweight and diabetes, and how its serious form, NASH, develops and leads to cirrhosis and liver cancer. His discovery that cholesterol damages liver cells to provoke inflammation is fundamental to devising effective NASH treatments. Farrell led Asian-Pacific guidelines on prevention and management of NASH, a world first, and on prevention of liver cancer. He has been lead investigator of NIH and NHMRC program and project grants, supervised 26 PhD candidates (6 now run their own labs), and published 4 books, more than 220 scientific articles and 140 reviews, editorials and chapters.

Director of Pathology
Peter MacCallum Cancer Centre

Stephen Fox is an internationally recognised anatomical and molecular pathologist. He is known for his research in the field of tumour blood vessel formation where he elucidated the mechanism by which a tumour establishes a blood supply that is critical to its growth and spread. He has shown the importance of these in breast tumours and its effect on patient response to treatment. He has developed and implemented novel molecular cancer testing from research to diagnostic laboratories and written several Australian guidelines that has changed the way laboratories test for genetic changes in cancer.

Foundation Chair of Dementia Research, Director, Clem Jones Centre for Ageing Dementia Research
Queensland Brain Institute, The University of Queensland

Alzheimer’s Disease is characterized by amyloid plaques and tau tangles. Understanding their role in pathology is crucial for developing a treatment for this yet incurable disease.  Professor Jürgen Götz generated the first transgenic mouse model with a tau pathology.  By combining a transgenic with a transplantation approach he proved the amyloid cascade hypothesis, a concept central in the field, and showed that amyloid induces a tau pathology.  He also demonstrated that tau is needed for amyloid to exert toxicity, by ‘axonal’ tau assuming a previously unidentified function in dendrites.  He developed a novel scanning ultrasound approach to reduce amyloid toxicity.

Head, Tumour Biology and Targeting Program
Children’s Cancer Institute

Professor Maria Kavallaris is an outstanding research leader who has made seminal discoveries on mechanisms of clinical drug resistance and tumour aggressiveness in childhood and adult cancers. Recognised as a world leader in cancer and microtubules, her discoveries have led to patents and industry linkages for the development of cancer therapeutics.   Professor Kavallaris is a founding Director of the Australian Centre for NanoMedicine at UNSW Australia, an innovative cross‐disciplinary initiative developing nanotechnology for medical applications. Professor Kavallaris has demonstrated outstanding leadership in medical research advocacy, peer review, mentoring and advanced research policy.

Head, Department of Clinical Medicine
Macquarie University

Professor Kefford is Professor of Cancer Medicine and Head of the Department of Clinical Medicine at Macquarie University, Sydney and Co‐Director of Research at Melanoma Institute Australia. He is an internationally acclaimed and highly respected clinical investigator in melanoma and a national leader in academic medicine and medical research. He has a lifelong record of commitment and service to Australian medical research, peer review and professional and community education in oncology. He contributed to the mapping and characterisation of the major melanoma susceptibility genes and has played a leading role in the development of life‐extending drug treatments for melanoma patients.

Our Fellows sit at the heart of everything we do. They represent Australia’s leading minds in health and medical sciences, having been recognised for their clinical, non-clinical, leadership, industry and research contributions.

To be considered for election to the Academy’s Fellowship, a candidate must show exceptional professional achievement in a field related to health and/or medicine.

Fellows contribute to the projects and activities of the Academy and must be willing to be active participants.

Successful Fellowship candidates will have shown:

  • Outstanding leadership in their field.
  • Significant and ongoing involvement with issues of health care, prevention of disease, education, research, and health services policy and delivery.

Candidates for Fellowship should meet the following criteria:

  • National and International recognition for excellence in health and medical science
  • Significant, sustained and ongoing contributions to advance health and medical science in Australia (relative to opportunity)
  • Contribution to the profession through leadership and mentorship
  • Raised public understanding and promoting health and medical science in the broader community

Download criteria for Fellowship

Each year, current Fellows of the Academy are invited to nominate up to four new candidates who meet the criteria and fulfil the required expectations.

To ensure the Academy has a representative and diverse membership, Fellows nominating two new candidates are asked to include only a maximum of one man, and Fellows nominating four new candidates are asked to include only a maximum of two men.

How to make a nomination

Fellows wishing to nominate a candidate for Fellowship should contact the secretariat to confirm candidate eligibility and receive and instructions on how to submit the completed nomination documentation online. 

Fellows wishing to nominate a candidate for a Corresponding Fellowship should contact the secretariat for more information.

Secretariat contact details
Email: [email protected]

Phone: 07 3102 7220

Nomination guidelines for ordinary Fellowship

October 2023
Newly elected Fellows of 2023 are inducted at the Annual Meeting.

18 September 2023- 30 November 2023
Nominations are invited from existing Fellows until the closing date of 30 November.

December 2023
Nominations allocated to Selection Committees.

January – April 2024
Referees’ reports sought.

Early May 2024
Selection Committees meet to consider nominations and provide final recommendations to the Council.

Early-to-mid-July 2024
Council meets to finalise recommendations.

Late July 2024
Full Fellowship invited to comment on recommended new fellows.

August 2024
Election results are shared with proposers and candidates (under embargo).

October 2024
Newly elected Fellows of 2024 inducted at the Annual Meeting.

Keep up to date with the latest news

By providing your email address, you consent to it being added to our mailing list.